Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
The DOI matches its Crossref record; 106 of the 106 references it cites were found in a registry or an index.
Abstract
Oestrogen-receptor-positive breast cancer is the most common subtype of breast cancer. Endocrine therapies that target the dependence of this subtype on the oestrogen receptor have substantial activity, yet the development of resistance to therapy is inevitable in advanced cancer. Major progress has been made in identifying the drivers of oestrogen-receptor-positive breast cancer and the mechanisms of resistance to endocrine therapy. This progress has translated into major advances in the treatment of advanced breast cancer, with several targeted therapies that enhance the efficacy of endocrine therapy; inhibitors of mTOR and inhibitors of the cyclin-dependent kinases CDK4 and CDK6 substantially improve progression-free survival. A new wave of targeted therapies is being developed, including inhibitors of PI3K, AKT, and HER2, and a new generation of oestrogen-receptor degraders. Considerable challenges remain in patient selection, deciding on the most appropriate order in which to administer therapies, and establishing whether cross-resistance occurs between therapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Treatment resistance, however, is a significant clinical problem that may be overcome by combining endocrine therapies with agents targeting resistance mechanisms.2”
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Maehama, T., & Dixon, J. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13375 · Cited by 3,104
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationTutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Self-citationSynthesis and Function of 3-Phosphorylated Inositol Lipids
Vanhaesebroeck, B., Leevers, S. J., Ahmadi, K., Timms, J., Katso, R., Driscoll, P. C., Woscholski, R., Parker, P. J., & Waterfield, M. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.535 · Cited by 1,535
(2015) · The Lancet · doi:10.1016/s0140-6736(15)61074-1 · Cited by 1,520
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Hsieh, A. C., Liu, Y., Edlind, M. P., Ingolia, N. T., Janes, M. R., Sher, A., Shi, E. Y., Stumpf, C. R., Christensen, C., Bonham, M. J., et al. (2012) · Nature · doi:10.1038/nature10912 · Cited by 1,313
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Toy, W., Shen, Y., Won, H., Green, B., Sakr, R. A., Will, M., Li, Z., Gala, K., Fanning, S., King, T. A., et al. (2013) · Nature Genetics · doi:10.1038/ng.2822 · Cited by 1,248
Shou, J., Massarweh, S., Osborne, C. K., Wakeling, A. E., Ali, S., Weiss, H., & Schiff, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,153
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Robinson, D. R., Wu, Y.-M., Vats, P., Su, F., Lonigro, R. J., Cao, X., Kalyana-Sundaram, S., Wang, R., Ning, Y., Hodges, L., et al. (2013) · Nature Genetics · doi:10.1038/ng.2823 · Cited by 1,145
Whitman, M., Downes, C. P., Keeler, M., Keller, T., & Cantley, L. (1988) · Nature · doi:10.1038/332644a0 · Cited by 1,016
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells
Lawson, D. A., Bhakta, N. R., Kessenbrock, K., Prummel, K. D., Yu, Y., Takai, K., Zhou, A., Eyob, H., Balakrishnan, S., Wang, C.-Y., et al. (2015) · Nature · doi:10.1038/nature15260 · Cited by 893
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., Koboldt, D. C., Monsey, J., Goel, N., Aronson, A. B., Li, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0349 · Cited by 868
Herrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
Self-citationPatnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3061 · Cited by 722
Self-citationBachelot, T., Bourgier, C., Cropet, C., Ray-Coquard, I., Ferrero, J.-M., Freyer, G., Abadie-Lacourtoisie, S., Eymard, J.-C., Debled, M., Spaëth, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.0708 · Cited by 703
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Iyer, G., Hanrahan, A. J., Milowsky, M. I., Al-Ahmadie, H., Scott, S. N., Janakiraman, M., Pirun, M., Sander, C., Socci, N. D., Ostrovnaya, I., et al. (2012) · Science · doi:10.1126/science.1226344 · Cited by 690
Bendell, J. C., Rodon, J., Burris, H. A., de Jonge, M., Verweij, J., Birle, D., Demanse, D., De Buck, S. S., Ru, Q. C., Peters, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1360 · Cited by 684
Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8415 · Cited by 636
Baselga, J., Semiglazov, V., van Dam, P., Manikhas, A., Bellet, M., Mayordomo, J., Campone, M., Kubista, E., Greil, R., Bianchi, G., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.8391 · Cited by 636
Schiavon, G., Hrebien, S., Garcia-Murillas, I., Cutts, R. J., Pearson, A., Tarazona, N., Fenwick, K., Kozarewa, I., Lopez-Knowles, E., Ribas, R., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac7551 · Cited by 575
Self-citationPiccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu456 · Cited by 574
Self-citationMiller, T. W., Hennessy, B. T., González-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., García-Echeverría, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 551
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu385 · Cited by 540
Oncogenic Mutations of PIK3CA in Human Cancers
Samuels, Y., & Velculescu, V. E. (2004) · Cell Cycle · doi:10.4161/cc.3.10.1164 · Cited by 538
Maira, S.-M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., Schnell, C., Guthy, D., Nagel, T., Wiesmann, M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0474 · Cited by 529
Chan, S., Scheulen, M. E., Johnston, S., Mross, K., Cardoso, F., Dittrich, C., Eiermann, W., Hess, D., Morant, R., Semiglazov, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.66.130 · Cited by 468
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438
Bosch, A., Li, Z., Bergamaschi, A., Ellis, H., Toska, E., Prat, A., Tao, J. J., Spratt, D. E., Viola-Villegas, N. T., Castel, P., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4442 · Cited by 432
Yardley, D. A., Ismail-Khan, R. R., Melichar, B., Lichinitser, M., Munster, P. N., Klein, P. M., Cruickshank, S., Miller, K. D., Lee, M. J., & Trepel, J. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.7251 · Cited by 423
André, F., Bachelot, T., Commo, F., Campone, M., Arnedos, M., Dieras, V., Lacroix-Triki, M., Lacroix, L., Cohen, P., Gentien, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70611-9 · Cited by 404
deGraffenried, L. A., Friedrichs, W. E., Russell, D. H., Donzis, E. J., Middleton, A. K., Silva, J. M., Roth, R. A., & Hidalgo, M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0035 · Cited by 387
Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells
Muranen, T., Selfors, L. M., Worster, D. T., Iwanicki, M. P., Song, L., Morales, F. C., Gao, S., Mills, G. B., & Brugge, J. S. (2012) · Cancer Cell · doi:10.1016/j.ccr.2011.12.024 · Cited by 384
Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
Mehta, R. S., Barlow, W. E., Albain, K. S., Vandenberg, T. A., Dakhil, S. R., Tirumali, N. R., Lew, D. L., Hayes, D. F., Gralow, J. R., Livingston, R. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1201622 · Cited by 371
Reactivation of multipotency by oncogenic PIK3CA induces breast tumour heterogeneity
Van Keymeulen, A., Lee, M. Y., Ousset, M., Brohée, S., Rorive, S., Giraddi, R. R., Wuidart, A., Bouvencourt, G., Dubois, C., Salmon, I., et al. (2015) · Nature · doi:10.1038/nature14665 · Cited by 354
Miller, T. W., Balko, J. M., Fox, E. M., Ghazoui, Z., Dunbier, A., Anderson, H., Dowsett, M., Jiang, A., Smith, R. A., Maira, S.-M., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0101 · Cited by 346
Lehmann, B. D., Bauer, J. A., Schafer, J. M., Pendleton, C. S., Tang, L., Johnson, K. C., Chen, X., Balko, J. M., Gómez, H., Arteaga, C. L., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0406-x · Cited by 342
Boulay, A., Rudloff, J., Ye, J., Zumstein-Mecker, S., O'Reilly, T., Evans, D. B., Chen, S., & Lane, H. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2402 · Cited by 335
Elkabets, M., Vora, S., Juric, D., Morse, N., Mino-Kenudson, M., Muranen, T., Tao, J., Campos, A. B., Rodon, J., Ibrahim, Y. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005747 · Cited by 332
Genomic Characterization of Primary Invasive Lobular Breast Cancer
Desmedt, C., Zoppoli, G., Gundem, G., Pruneri, G., Larsimont, D., Fornili, M., Fumagalli, D., Brown, D., Rothé, F., Vincent, D., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0334 · Cited by 318
Robertson, J. F. R., Llombart-Cussac, A., Rolski, J., Feltl, D., Dewar, J., Macpherson, E., Lindemann, J., & Ellis, M. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1136 · Cited by 310
Wagle, N., Grabiner, B. C., Van Allen, E. M., Hodis, E., Jacobus, S., Supko, J. G., Stewart, M., Choueiri, T. K., Gandhi, L., Cleary, J. M., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0353 · Cited by 281
Wolff, A. C., Lazar, A. A., Bondarenko, I., Garin, A. M., Brincat, S., Chow, L., Sun, Y., Neskovic-Konstantinovic, Z., Guimaraes, R. C., Fumoleau, P., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3331 · Cited by 272
Ellard, S. L., Clemons, M., Gelmon, K. A., Norris, B., Kennecke, H., Chia, S., Pritchard, K., Eisen, A., Vandenberg, T., Taylor, M., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3033 · Cited by 258
Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
Akinleye, A., Avvaru, P., Furqan, M., Song, Y., & Liu, D. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-88 · Cited by 254
Hortobagyi, G. N., Chen, D., Piccart, M., Rugo, H. S., Burris, H. A., Pritchard, K. I., Campone, M., Noguchi, S., Perez, A. T., Deleu, I., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.1971 · Cited by 248
Development of Cell-Cycle Inhibitors for Cancer Therapy
Dickson, M. A., & Schwartz, G. K. (2009) · Current Oncology · doi:10.3747/co.v16i2.428 · Cited by 246
Ellis, M. J., Llombart-Cussac, A., Feltl, D., Dewar, J. A., Jasiówka, M., Hewson, N., Rukazenkov, Y., & Robertson, J. F. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5831 · Cited by 238
Crowder, R. J., Phommaly, C., Tao, Y., Hoog, J., Luo, J., Perou, C. M., Parker, J. S., Miller, M. A., Huntsman, D. G., Lin, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4450 · Cited by 218
Ilic, N., Utermark, T., Widlund, H. R., & Roberts, T. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108237108 · Cited by 211
Osborne, C. K., Neven, P., Dirix, L. Y., Mackey, J. R., Robert, J., Underhill, C., Schiff, R., Gutierrez, C., Migliaccio, I., Anagnostou, V. K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1869 · Cited by 179
Self-citationSoria, J.-C., DeBraud, F., Bahleda, R., Adamo, B., Andre, F., Dientsmann, R., Delmonte, A., Cereda, R., Isaacson, J., Litten, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu390 · Cited by 173
Hu, W., Sung, T., Jessen, B. A., Thibault, S., Finkelstein, M. B., Khan, N. K., & Sacaan, A. I. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1421 · Cited by 171
Hong, D. S., Bowles, D. W., Falchook, G. S., Messersmith, W. A., George, G. C., O'Bryant, C. L., Vo, A. C. H., Klucher, K., Herbst, R. S., Eckhardt, S. G., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0714 · Cited by 169
Robertson, J. F., Ferrero, J.-M., Bourgeois, H., Kennecke, H., de Boer, R. H., Jacot, W., McGreivy, J., Suzuki, S., Zhu, M., McCaffery, I., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70026-3 · Cited by 165
Cyclins and CDKS in development and cancer: lessons from genetically modified mice
Santamaria, D. (2006) · Frontiers in Bioscience · doi:10.2741/1871 · Cited by 165
Markman, B., Tabernero, J. M., Krop, I. E., Shapiro, G. I., Siu, L. L., Chen, L. C., Mita, M. M., Cuero, M. M., Stutvoet, S., Birle, D. C., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds011 · Cited by 158
Awada, A. H., Cardoso, F., Fontaine, C., Dirix, L. Y., Grève, J. D., Sotiriou, C. P., Steinseifer, J., Wouters, C., Tanaka, C., Zoellner, U., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.10.003 · Cited by 155
The Mammalian Cell Cycle: An Overview
Harper, J. V., & Brooks, G. (2004) · Humana Press eBooks · doi:10.1385/1-59259-857-9:113 · Cited by 153
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
Serra, V., Eichhorn, P. J. A., García-García, C., Ibrahim, Y. H., Prudkin, L., Sánchez, G., Rodríguez, O., Antón, P., Parra, J.-L., Marlow, S., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci66343 · Cited by 136
Rugo, H. S., Pritchard, K. I., Gnant, M., Noguchi, S., Piccart, M., Hortobagyi, G., Baselga, J., Perez, A., Geberth, M., Csoszi, T., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu009 · Cited by 130
Metastatic Breast Cancer, Version 1.2012
Carlson, R. W., Allred, D. C., Anderson, B. O., Burstein, H. J., Edge, S. B., Farrar, W. B., Forero, A., Giordano, S. H., Goldstein, L. J., Gradishar, W. J., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0086 · Cited by 118
Finn, R. S., Martin, M., Rugo, H. S., Jones, S. E., Im, S.-A., Gelmon, K. A., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.507 · Cited by 109
Ross, J. S., Gay, L. M., Wang, K., Ali, S. M., Chumsri, S., Elvin, J. A., Bose, R., Vergilio, J., Suh, J. H., Yelensky, R., et al. (2016) · Cancer · doi:10.1002/cncr.30102 · Cited by 101
Carpenter, J. T., Roché, H., Campone, M., Colomer, R., Jagiello-Gruszfeld, A., Moore, L., D’Amore, M., Kong, S., Boni, J., & Baselga, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.564 · Cited by 98
Consensus on precision medicine for metastatic cancers: a report from the MAP conference
Swanton, C., Soria, J., Bardelli, A., Biankin, A. V., Caldas, C., Chandarlapaty, S., de Koning, L., Dive, C., Feunteun, J., Leung, S.-Y., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw192 · Cited by 98
Rugo, H. S., Delord, J., Im, S., Ott, P. A., Piha-Paul, S. A., Bedard, P. L., Sachdev, J. C., Tourneau, C. L., van Brummelen, E. M. J., Varga, A., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-s5-07 · Cited by 97
Baselga, J. M., Im, S., Iwata, H., Clemons, M. J., Ito, Y., Awada, A. H., Chia, S., Jagiełło-Gruszfeld, A., Pistilli, B., Tseng, L.-M., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-s6-01 · Cited by 89
Treilleux, I., Arnedos, M., Cropet, C., Wang, Q., Ferrero, J.-M., Abadie‐Lacourtoisie, S., Lévy, C., Legouffe, É., Lortholary, A. H., Pujade-Lauraine, É., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu497 · Cited by 88
Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013
King, T. A., Lyman, J. P., Gönen, M., Voci, A. E., Brot, M. D., Boafo, C., Sing, A. P., Hwang, E. S., Alvarado, M. D., Liu, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.1960 · Cited by 86
Phase II trial of temsirolimus in patients with metastatic breast cancer
Fleming, G. F., Ma, C. X., Huo, D., Sattar, H. A., Tretiakova, M., Li, L., Hahn, O. M., Olopade, F. O., Nanda, R., Hoffman, P. C., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1910-7 · Cited by 85
Loi, S., Michiels, S., Baselga, J., Bartlett, J. M. S., Singhal, S. K., Sabine, V. S., Sims, A. H., Sahmoud, T., Dixon, J. M., Piccart, M. J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053292 · Cited by 84
PI3K in cancer–stroma interactions: bad in seed and ugly in soil
Hirsch, E., Ciraolo, E., Franco, I., Ghigo, A., & Martini, M. (2013) · Oncogene · doi:10.1038/onc.2013.265 · Cited by 77
Inhibition of the p110α isoform of PI 3-kinase stimulates nonfunctional tumor angiogenesis
Soler, A., Serra, H., Pearce, W., Angulo, A., Guillermet-Guibert, J., Friedman, L. S., Viñals, F., Gerhardt, H., Casanovas, O., Graupera, M., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121571 · Cited by 69
Comparison of Akt/mTOR signaling in primary breast tumors and matched distant metastases
Akçakanat, A., Şahin, A. A., Shaye, A. N., Velasco, M. A. D., & Meric‐Bernstam, F. (2008) · Cancer · doi:10.1002/cncr.23456 · Cited by 66
Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortes, J., Diéras, V., Patt, D. A., Wildiers, H., Frenzel, M., Koustenis, A., & Baselga, J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.510 · Cited by 65
Bowles, D. W., Ma, W. W., Senzer, N., Brahmer, J. R., Adjei, A. A., Davies, M., Lazar, A. J., Vo, A., Peterson, S., Walker, L., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.474 · Cited by 62
Krop, I., Johnston, S., Mayer, I. A., Dickler, M., Ganju, V., Forero-Torres, A., Melichar, B., Morales, S., de Boer, R., Gendreau, S., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.sabcs14-s2-02 · Cited by 60
Di Cosimo, S., Sathyanarayanan, S., Bendell, J. C., Cervantes, A., Stein, M. N., Braña, I., Roda, D., Haines, B. B., Zhang, T., Winter, C. G., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0940 · Cited by 55
Yamamoto, K., Graziani, A., Carpenter, C., Cantley, L. C., & Lapetina, E. G. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)45672-4 · Cited by 54
Juric, D., Münster, P. N., Campone, M., Ismail-Khan, R. R., García‐Estévez, L., Hamilton, E. P., Becerra, C. R., Boer, R. H. D., Hui, R., Gonçalvès, A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.568 · Cited by 33
Warenius, H. M., Kilburn, J., Essex, J. W., Maurer, R. I., Blaydes, J. P., Agarwala, U., & Seabra, L. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-72 · Cited by 27
Dickler, M. N., Bardia, A., Mayer, I. A., Winer, E. P., Rix, P. J., Hager, J., Chen, M., Chan, I. T., Chow‐Maneval, E., Arteaga, C. L., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-ct231 · Cited by 25
A Lipid Kinase Cousin Cooperates to Promote Cancer
Beagle, B. R., & Fruman, D. A. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.020 · Cited by 18
Hyman, D. M., Smyth, L. M., Bedard, P. L., Oza, A. M., Dean, E. J., Armstrong, A. C., Lima, J. P. D. S. N., Bando, H., Kabos, P., Fidalgo, J. A. P., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-15-b109 · Cited by 18
Jankú, F., Juric, D., Cortés, J., Rugo, H. S., Burris, H. A., Schüler, M., Deschler-Baier, B., Middleton, M. R., Gil-Martín, M., Berlin, J. D., et al. (2015) · Cancer Research · doi:10.1158/1538-7445.sabcs14-pd5-5 · Cited by 17
Phase II trial of neratinib for HER2 mutated, non-amplified metastatic breast cancer (HER2mut MBC).
Ma, C. X., Bose, R., Gao, F., Freedman, R. A., Pegram, M. D., Blackwell, K., Bedard, P. L., Hayes, D. F., Goetz, M. P., Niravath, P. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.516 · Cited by 16
Ellis, M. J., Bondarenko, I., Trishkina, E., Dvorkin, M. V., Panasci, L., Manikhas, A., Shparyk, Y. V., Cardona‐Huerta, S., Cheung, K., Philco-Salas, M. J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw435.04 · Cited by 15
Juric, D., Saura, C., Cervantes, A. M. R., Kurkjian, C. D., Patel, M., Sachdev, J. C., Mayer, I. A., Krop, I. E., Oliveira, M., Sanabria, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.sabcs13-pd1-3 · Cited by 13
Chandarlapaty, S., Sung, P., Chen, D., He, W., Samoila, A., You, D., Bhatt, T., Patel, P. T., Voi, M., Gnant, M., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-s2-07 · Cited by 13
Arnedos, M., Cheaib, B., Bayar, M. A., Michiels, S., Scott, V., Adam, J., Leroux-Kozal, V., Marty, V., Mazouni, C., Sarfati, B., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-ct041 · Cited by 13
Rugo, H. S., Chambers, M. S., Litton, J. K., Mayer, I. A., Rogerio, J. W., DeMars, L. R., Geronimo, J., Warsi, G. M., & Meiller, T. F. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.tps661 · Cited by 3
AZD5363, a catalytic pan-Akt inhibitor, in Akt1 E17K mutation positive advanced solid tumors
Hyman, D. M., Smyth, L. M., Bedard, P. L., Oza, A. M., Dean, E. J., Armstrong, A. C., Lima, J. P. D. S. N., Bando, H., Kabos, P., Fidalgo, J. A. P., et al. (2015) · Research Explorer (The University of Manchester) · Cited by 3
Cited by
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Self-citationLoibl, S., Poortmans, P., Morrow, M., Denkert, C., & Curigliano, G. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32381-3 · Cited by 1,648
Self-citationO'Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., Garcia-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 650
Self-citationPI3K inhibitors are finally coming of age
Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00209-1 · Cited by 476
Waddell, I. S., & Orfila, C. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2061909 · Cited by 211
Metadata
- Authors
- Turner, N. C., Neven, P., Loibl, S., & Andre, F.
- Affiliations
- Institute of Cancer Research (GB)
- Universitair Ziekenhuis Leuven (BE)
- German Breast Group (DE)
- Corresponding author
- Loibl, Sibylle
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 389
- Issue
- 10087
- Pages
- 2403-2414
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2560409587
- Cited by
- 205
- References
- 106
- Citations by year
- 2026: 14 · 2025: 10 · 2024: 18 · 2023: 22 · 2022: 25 · 2021: 25 · 2020: 31 · 2019: 21 · 2018: 29 · 2017: 10
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- estrogen receptor-positive breast cancer, advanced breast cancer, endocrine therapy, endocrine therapy resistance, mTOR inhibitors, CDK4/6 inhibitors, PI3K/AKT inhibitors, HER2 inhibitors, targeted therapy, progression-free survival, cross-resistance, patient selection
- MeSH terms
- Antineoplastic Agents, Breast Neoplasms, Female, Humans, Nuclear Proteins, Piperazines, Pyridines, Receptors, Estrogen, Transcription Factors, Aromatase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, TOR Serine-Threonine Kinases, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.